LNP-mRNA and linker macrophages for connecting t cells, macrophages and tumor cells and applications thereof
By delivering chimeric antigen receptors and CD80 mRNA targeting tumor cells through lipid nanoparticles and editing macrophages, the stability and activation problems of existing antibodies in tumor treatment are solved, achieving efficient killing of tumor cells and long-term immune surveillance.
Patent Information
- Application Number
- CN202610359030.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-23
- Publication Date
- 2026-06-23
AI Technical Summary
Existing bispecific or multispecific antibodies in tumor cell immunotherapy suffer from problems such as unreasonable target combinations, structural instability, overactivation of the immune system, complex preparation processes, and efficacy affected by the heterogeneity of the tumor microenvironment, resulting in low clinical conversion rates.
Lipid nanoparticles (LNP-mRNA) are used to encapsulate chimeric antigen receptors, CD80 mRNA, and anti-CD3 single-chain antibody mRNA targeting tumor cells. Macrophages are then edited to express CAR and CD80, providing dual signals for T cell activation and achieving synergistic effects among macrophages, T cells, and tumor cells.
It achieves highly efficient killing of tumor cells, promotes the formation of memory T cells, provides long-term tumor suppression and immune surveillance, reduces adverse reactions caused by overactivation, and improves treatment efficacy.
Smart Images

Figure CN122256434A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and in particular to an LNP-mRNA and a connector macrophage for connecting T cells, macrophages and tumor cells, and their applications. Background Technology
[0002] In recent years, bispecific and trispecific antibodies have been widely developed for cell immunotherapy of solid tumors. These antibodies usually act as connectors between two or three types of cells to promote the activation of immune cells and thus enhance their tumor-killing ability, or enhance tumor-killing function by bringing immune cells and tumor cells closer together. There are also trispecific antibodies that bring tumor cells and T cells closer together and can also activate T cells to kill tumor cells. However, bispecific or multispecific antibodies still have many defects and shortcomings: for example, (1) the rationality of the target combination will directly affect the therapeutic effect, and there may be competition between targets that are blindly combined. (2) Bispecific antibodies are composed of two different antibody fragments, which are prone to mismatch or structural instability, resulting in a short half-life in vivo and affecting efficacy. (3) Bispecific or trispecific antibodies may aggravate adverse reactions due to overactivation of the immune system. (4) The preparation process of bispecific antibodies is more complex than that of monoclonal antibodies, and it is necessary to overcome technical bottlenecks such as the difficulty of antibody fragment assembly and purification. For example, traditional methods are prone to producing byproducts, which require additional engineering modifications to improve stability and further increase production costs. (5) The efficacy of bispecific antibody therapy is significantly affected by the heterogeneity of the patient's tumor microenvironment, and some patients cannot benefit due to differences in genotype or immune status. Although there are a large number of bispecific antibody drugs under development worldwide, the clinical translation rate is low.
[0003] In view of this, the present invention is hereby proposed. Summary of the Invention
[0004] The primary objective of this invention is to provide a lipid nanoparticle (LNP-mRNA) to address the aforementioned technical problems.
[0005] A second objective of this invention is to provide the application of the above-mentioned lipid nanoparticles in the preparation of products for treating tumors.
[0006] A third objective of this invention is to provide an engineered macrophage with connector function (connector macrophage).
[0007] To achieve the above objectives, the following technical solution is adopted: In a first aspect, the present invention provides a lipid nanoparticle that encapsulates mRNA of a chimeric antigen receptor targeting tumor cells, CD80 mRNA, and mRNA of an anti-CD3 single-chain antibody.
[0008] As a further technical solution, the tumor includes liver cancer and ovarian cancer.
[0009] As a further technical solution, the amino acid sequence of the mRNA-encoded protein targeting the chimeric antigen receptor of liver cancer cells is shown in SEQ ID NO.1.
[0010] As a further technical solution, the amino acid sequence of the mRNA-encoded protein targeting the chimeric antigen receptor of ovarian cancer cells is shown in SEQ ID NO.2.
[0011] As a further technical solution, the amino acid sequence of the CD80 mRNA-encoded protein is shown in SEQ ID NO.3.
[0012] As a further technical solution, the amino acid sequence of the protein encoded by the mRNA of the anti-CD3 single-chain antibody is shown in SEQ ID NO.4.
[0013] As a further technical solution, the lipid nanoparticles include ionizable lipids (SM-102), phospholipids (DSPC), cholesterol (Chol), and dimyristic-rac-glycerol-PEG (DMG-PEG).
[0014] As a further technical solution, the molar ratio of the ionizable lipids, phospholipids, cholesterol and myristoyl-rac-glycerol-PEG is 50 : 10 : 38.5 : 1.5.
[0015] Secondly, the present invention provides the application of the above-mentioned lipid nanoparticles in the preparation of products for treating tumors.
[0016] Thirdly, the present invention provides an engineered macrophage with a connector function, wherein the engineered macrophage is a macrophage expressing the chimeric antigen receptor, CD80 and anti-CD3 single-chain antibody targeting the tumor cells.
[0017] Compared with the prior art, the present invention has the following beneficial effects: The lipid nanoparticles provided by this invention encapsulate chimeric antigen receptor (CAR) mRNA, CD80 mRNA, and anti-CD3 single-chain antibody mRNA targeting tumor cells, enabling simultaneous delivery of all three mRNAs and uptake by macrophages and tumor cells. After uptake by macrophages, CAR, CD80, and anti-αCD3 antibodies can be expressed simultaneously. Specifically, the CAR expressed by macrophages can link macrophages and tumor cells, while the expressed anti-αCD3 antibody can link macrophages and T cells. The anti-αCD3 antibody provides the first signal for T cell activation, while CD80 compensates for insufficient endogenous expression, ensuring a sufficient second signal for T cell activation; their synergistic effect guarantees normal T cell activation. Tumor cells, after uptake of the lipid nanoparticles, can also express CD80 and αCD3, providing both the first and second signals for T cell activation, allowing macrophages, T cells, and tumor cells to bind together. CAR-macrophages and activated T cells can work together to kill tumors. At the same time, CAR-macrophages can also present antigens to T cells, exerting an antigen expansion effect, promoting the formation of memory T cells, and achieving long-term tumor surveillance and inhibition. Attached Figure Description
[0018] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0019] Figure 1 : A schematic diagram illustrating the principle of lipid nanoparticles and in vivo engineered connector M cells for tumor therapy according to the present invention; Figure 2 CAR, anti-CD3 scFv (αCD3), and CD80 mRNA delivered by LNP were successfully expressed in the BMDM of C57BL / 6 mice; AB: expression of GPC3-CAR, anti-CD3 scFv (αCD3), and MSLN-CAR mRNA on the BMDM surface 24 hours after LNP delivery was detected by flow cytometry; C: expression of CD80 mRNA delivered by LNP on the BMDM surface 24 hours after delivery was detected by flow cytometry and the mean fluorescence intensity (MFI) was statistically analyzed. Figure 3The following are examples of experiments: BMDM expressing αCD3 can directly bind to CD3+ T cells. A: After co-culturing BMDM with T cells for 12 hours, the attachment of T cells to the surface of wild-type (WT), GFP-expressing, and GPC3-CAR-expressing BMDMs was observed under a microscope. B: After co-culturing BMDM with T cells for 12 hours, the attachment of T cells to the surface of BMDM simultaneously expressing αCD3 and CD80 was observed under a microscope. C: After co-culturing BMDM with T cells for 12 hours, the attachment of T cells to the surface of BMDM simultaneously expressing αCD3, CD80, and GPC3-CAR was observed under a microscope. D: The attachment of T cells around wild-type (WT), GFP-expressing, GPC3-CAR-expressing, CD80-expressing, αCD3-expressing, and co-expressing αCD3v and CD80 BMDMs was observed using immunofluorescence staining. Figure 4 The study showed that BMDM co-expressing αCD3 and CD80 had a better activation effect on T cells than BMDM expressing only αCD3. Specifically, A: flow cytometry analysis was used to detect the proportion of CD69+ T cells after co-culturing BMDM expressing different molecules with T cells for 72 hours, and the results were statistically analyzed. B: flow cytometry analysis was used to detect the proportion of CD69+ T cells after co-culturing BMDM expressing different molecules with T cells for 10 days, and the results were statistically analyzed. Figure 5 BMDM co-expressing αCD3 and CD80 significantly enhanced the anti-apoptotic ability of T cells and promoted T cell proliferation more effectively than BMDM expressing only αCD3. Specifically, A: After co-culturing BMDM expressing different molecules with CFSE-stained T cells for 72 hours, the fluorescence intensity of CFSE and the percentage of proliferating cells in T cells were detected by flow cytometry; B: After co-culturing BMDM expressing different molecules with T cells for 72 hours, the expression level and mean fluorescence intensity of intracellular Bcl2 in T cells were analyzed by flow cytometry. Figure 6 BMDM co-expressing αCD3 and CD80 significantly enhanced the secretion of tumor-killing cytokines by T cells; A: The concentration of IFNr in the supernatant after T cells were co-cultured with BMDM expressing different molecules for 72 hours by ELISA; B: The concentration of IL2 in the supernatant after T cells were co-cultured with BMDM expressing different molecules for 72 hours by ELISA; C: The concentration of graninase B in the supernatant after T cells were co-cultured with BMDM expressing different molecules for 72 hours by ELISA. Figure 7The study showed that T cells co-cultured with BMDM expressing αCD3+CD80 exhibited more active mitochondrial function. Specifically: A: Flow cytometry analysis was used to detect the expression level and mean fluorescence intensity of Mitotracker RedCMXRos in T cells after 72 hours of co-culturing with BMDM expressing different molecules; B: The Seahorse XF Pro analyzer was used to detect the change in oxygen consumption rate (OCR) of T cells over time after 96 hours of co-culturing with BMDM expressing different molecules; C: The Seahorse XF Pro analyzer was used to detect the basal respiration, maximum respiratory capacity, and reserve respiratory capacity of T cells after 96 hours of co-culturing with BMDM expressing different molecules. Figure 8 Human tumor antigens were successfully expressed on the surface of mouse tumor cells; among them, A: the expression level of human GPC3 in Hepa1-6 mouse liver cancer cells was detected by flow cytometry; B: the expression level of human MSLN in ID8 mouse ovarian cancer cells was detected by flow cytometry. Figure 9 BMDM cells expressing αCD3+CD80, combined with T cells, can exert superior tumor cell killing function compared to BMDM cells expressing only αCD3; among them, A: BMDM cells expressing different molecules, combined with T cells and Hepa1-6 GPC3+ Tumor cells were co-cultured with a mixture of BMDM:T:tumor cells at a ratio of 2:4:1 for 72 hours. The killing efficiency against tumor cells was then assessed using a luciferase assay. B: BMDM expressing different molecules in conjunction with T cells and Hepa1-6. MSLN+ After co-culturing tumor cells at a ratio of BMDM:T:tumor cells = 2:4:1 for 72 hours, the killing efficiency against tumor cells was detected by luciferase assay. Figure 10 The formation of T-cell-macrophage-tumor cell aggregates was observed under confocal microscopy. Figure 11 Tumor cells expressing αCD3 and αCD3+CD80 can also stimulate T cells, thereby inducing tumor cell death. Specifically, A: the survival of tumor cells after co-culturing four types of Hepa1-6-Luciferase-tdtomato tumor cells expressing GFP, CD80, αCD3, and αCD3+CD80 with T cells was observed using fluorescence microscopy; B: the killing efficiency of each group of tumor cells was detected using a luciferase assay. Figure 12 : The proportion of LNP uptake by different cells in tumor tissue; where AB: mouse Hepa1-6 GPC3+- The proportion of LNP uptake in CD45+ hepatocellular carcinoma cells and the proportion of various immune cells in CD45+ cells that uptake LNP in a Luciferase-tdtomato hepatocellular carcinoma model; CD: mouse ID8 MSLN+ - The proportion of LNP uptake by peritoneal CD45+ cells and the proportion of various immune cells among CD45+ cells that uptake LNP in the Luciferase-tdtomato ovarian cancer model. Figure 13 Intraperitoneal delivery of αCD3-CD80-MSLN-CAR mRNA LNP showed significant efficacy in treating MSLN-positive ovarian cancer; among which, A: ID8 MSLN+ - Experimental design and flowchart of the Luciferase-tdtomato ovarian cancer model; B: Observation of tumor growth in mice in each group by in vivo imaging; C: Statistical analysis of tumor burden in mice in each group at different treatment time points; D: Flow cytometry detection of the proportion of CD69+ T cells in mouse peritoneal cells; Figure 14 The αCD3-CD80-MSLN-CAR treatment group was able to resist re-challenge in MSLN-positive ovarian cancer; among them, A: ID8 MSLN+ - Experimental design and flowchart of the Luciferase-tdtomato ovarian cancer re-challenge model; B: Observation of tumor growth in mice of each group through in vivo imaging; C: Statistical analysis of tumor burden in mice of each group at different treatment time points; D: Statistical analysis of survival rate of mice of each group at different treatment time points. Figure 15 In vivo intravenous delivery of αCD3-CD80-GPC3-CAR mRNA LNP significantly inhibited in situ Hepa1-6 GPC3+ Hepatocellular carcinoma progression and prolonged survival in mice; among them, A: Hepa1-6 GPC3+ Luciferase-tdtomato liver cancer model and LNP A: Schematic diagram of the timeline of intravenous mRNA administration and in vivo bioluminescence imaging; B: Observation of tumor growth in mice of each group through in vivo imaging; C: Statistical analysis of tumor burden in mice of each group at different treatment time points; D: Statistical analysis of survival rate of mice of each group at different treatment time points. Figure 16 CAR αCD3 CD80 LNP treatment significantly enhances local CD8+ in tumors. + T cell infiltration and altered myeloid cell distribution; A: Representative images of multiplex immunofluorescence staining of tumor tissues from each group of mice, showing CD11b... + Myeloid cells (green), CD8 +Spatial distribution of T cells (purple) and nuclei (DAPI, blue); B: CD8 in tumor tissues of each group. + Quantitative analysis of T cell infiltration levels, comparing the GFP control group, αCD3 group, and CAR group. αCD3 CD80 group unit area CD8 + T cell number difference; C: CAR αCD3 High-magnification immunofluorescence image of the tumor region in the CD80 group, showing CD8 + T cells and CD11b + Localized aggregation and close adjacent distribution of myeloid cells; Figure 17 CAR αCD3 CD80 mRNA LNP-induced complete remission can establish a response targeting 50% of GPC3. + Durable immune memory in liver cancer; A: Schematic diagram of experimental design and Hepa1-650%. GPC3+ Cell phenotype identification; B: Monitoring the changes in subcutaneous tumor volume in the two groups of mice after tumor inoculation, and statistically comparing the tumor volume at each time point; Figure 18 CAR αCD3 CD80 mRNA and LNP synergistically enhance tumor invasion CD8 + Effector function of T cells; among which, A: flow cytometry detection of different mRNA LNP treatment groups (GFP control, CAR, αCD3, CD80 single drug and CAR) αCD3 CD80 combination) tumor-infiltrating CD8 + IFN in T cells B: Representative flow cytometry plots and quantitative analysis of γ expression; B: Flow cytometry detection of CD8 infiltrating tumors in different treatment groups. + Representative flow cytometry plots and quantitative analysis of CD107a, a degranulation marker in T cells; Figure 19 LNP treatment significantly increased memory T cells in tumor tissue and improved the immune microenvironment; among them, A: tumor infiltration CD8 in different treatment groups + T cells and CD4 + T cells contain CD44high and CD62L. + B: Flow cytometry analysis and statistical analysis of the proportion of memory T cells; C: Tumor infiltration CD4 in different treatment groups + Foxp3 in T cells+ Treg ratio and CD8 + Perforin in T cells + Comparison of cell proportions; C: CD206 expression level of tumor-associated macrophages and neutrophil expression level (CD11b) in different treatment groups. + Ly6G + (in China) and NK cells (CD3) - NK1.1 + Statistical analysis of the infiltration ratio. Detailed Implementation
[0020] The embodiments and examples of the present invention will be described in detail below. However, those skilled in the art will understand that the following embodiments and examples are for illustrative purposes only and should not be considered as limiting the scope of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention. Unless otherwise specified, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0021] In a first aspect, the present invention provides a lipid nanoparticle that encapsulates mRNA of a chimeric antigen receptor targeting tumor cells, CD80 mRNA, and mRNA of an anti-CD3 single-chain antibody.
[0022] This invention uses in vivo edited macrophages themselves as connectors. Figure 1By editing macrophages in vivo, they can simultaneously target two or more antigenic epitopes located on two different types of cells, theoretically enabling the connection between three types of cells and the activation of specific immune cells (T cells). This technology has the following advantages: (1) The combination of targets is flexible. As long as they can be expressed simultaneously in the same cell, it will not affect the survival of the cell itself. (2) There are no difficulties in the preparation process. Several individual mRNAs can be packaged using lipid nanoparticle (LNP) technology and delivered to target cells for expression. (3) Living cells can respond to changes in the microenvironment and play a more precise regulatory role. Signal networks can be formed between cells to fully exert the synergistic effect between multiple cells. (4) Using the endogenous co-stimulatory molecule CD80 as the second signal can activate the T cell's own negative feedback regulatory molecule CTLA4 to a certain extent, thereby reducing the severe CRS caused by overactivation. (5) Tumor cells can also express dual signals after taking up LNPs, which can ensure that the T cells that are pulled over by binding to the αCD3 expressed by the tumor cells are activated, rather than just undergoing apoptosis after the first signal stimulation, thus achieving a highly efficient killing effect on tumor cells. TAM, T cells and tumor cells can connect in pairs. (6) CAR-macrophages can also directly engulf and kill tumor cells, present tumor antigens to T cells, play an antigen expansion role, promote the formation of memory T cells, and achieve long-term tumor suppression and immune surveillance.
[0023] It should be noted that the three mRNAs can be loaded onto the same lipid nanoparticle or onto different lipid nanoparticles.
[0024] In some alternative implementations, the tumor includes, but is not limited to, liver cancer and ovarian cancer, or other tumors well known in the art.
[0025] In some optional embodiments of the present invention, the amino acid sequence of the mRNA-encoded protein targeting the chimeric antigen receptor of liver cancer cells with GPC3 is shown in SEQ ID NO.1.
[0026] MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADESTSTAYMELSSLRSEDT AVYYCTRFYSYTYWGQGTLVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSG TDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIKTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYIWAPLAGICVALLLSLIITLICRAKFSR SAETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQQRRRNPQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLYQGLSTATKDTYDALHMQTLAPR (SEQID NO.1).
[0027] In some alternative implementations, MSLN is used as the target, and the amino acid sequence of the mRNA-encoded protein of the chimeric antigen receptor for ovarian cancer cells is shown in SEQ ID NO.2.
[0028] MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFDLGFYFYACWVRQAPGKGLEWVSCIYTAGSGSTYYASWAKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCARSTANTRSTYYLNLWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSSLSASVGDRVTITCQASQRISSYLSWYQQKPGKVPKLLIYGASTLASGVPSRFSGSGS GTDFTLTISSLQPEDVATYYCQSYAYFDSNNWHAFGGGTKVEIKTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYIWAPLAGICVALLLSLIITLICRAK FSRSAETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQQRRRNPQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLYQGLSTATKDTYDALHMQTLAPR (SEQ ID NO.2).
[0029] In some alternative embodiments, the amino acid sequence of the protein encoded by the CD80 mRNA is shown in SEQ ID NO.3.
[0030] MACNCQLMQDTPLLKFPCPRLILLFVLLIRLSQVSSDVDEQLSKSVKDKVLLPCRYNSPHEDESEDRIYWQKHDKVVLSVIAGKLKVWPEYKNRTLYDNTTYSLIILGLVLSDRGTYSCVVQKKERGTYEVKHLALVKLSIKADFSTPNITESGN PSADTKRITCFASGGFPKPRFSWLENGRELPGINTTISQDPESELYTISSQLDFNTTRNHTIKCLIKYGDAHVSEDFTWEKPPEDPPDSKNTLVLFGAGFGAVITVVVIVVIIKCFCKHRSCFRRRNEASRETNNSLTFGPEEALAEQTVFL (SEQ ID NO.3).
[0031] In some alternative embodiments, the amino acid sequence of the protein encoded by the mRNA of the anti-CD3 single-chain antibody is shown in SEQ ID NO.4.
[0032] MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGKSLKLSCEASGFTFSGYGMHWVRQAPGRGLESVAYITSSSINIKYADAVKGRFTVSRDNAKNLLFLQMNILKSEDTAMYYCARFDWDKNYWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLPA SLGDRVTINCQASQDISNYLNWYQQKPGKAPKLLIYYTNKLADGVPSRFSGSGSGRDSSFTISSLESEDIGSYYCQQYYNYPWTFGPGTKLEIKTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYIWAPLAGICVALLLSLIITLIC (SEQ ID NO.4).
[0033] This invention does not impose specific limitations on the composition of lipid nanoparticles; lipid nanoparticles well known to those skilled in the art can be used. In some optional embodiments, the lipid nanoparticles include ionizable lipids (SM-102), phospholipids (DSPC), cholesterol (Chol), and dimyristic-rac-glycerol-PEG (DMG-PEG).
[0034] In some alternative embodiments, the molar ratio of the ionizable lipids, phospholipids, cholesterol, and dimyristic-rac-glycerol-PEG is 50:10:38.5:1.5.
[0035] Secondly, the present invention provides the application of the above-mentioned lipid nanoparticles in the preparation of products for treating tumors.
[0036] The LNP provided by this invention can edit macrophages to become connectors between T cells and tumor cells, and can be used to prepare products for treating tumors.
[0037] Thirdly, the present invention provides an engineered macrophage with a connector function, wherein the engineered macrophage is a macrophage expressing the chimeric antigen receptor, CD80 and anti-CD3 single-chain antibody targeting tumor cells.
[0038] By introducing chimeric antigen receptor mRNA, CD80 mRNA, and anti-CD3 single-chain antibody mRNA targeting tumor cells into macrophages, the macrophages express proteins translated from the introduced mRNAs. These macrophages can then bind to tumor cells and T cells, thereby bridging the gap between tumor cells and T cells and improving therapeutic efficacy. Unlike existing connectors, which are antibody modalities, the connector of this invention is an in vivo edited macrophage (cell modality), referred to as an in vivo TCE macrophage cell or in vivo TCE M cell, which is a cellular form.
[0039] The present invention will be further illustrated below with specific embodiments. However, it should be understood that these embodiments are merely for the purpose of more detailed illustration and should not be construed as limiting the present invention in any way.
[0040] Preparation Example 1 Four components—ionizable lipids (SM-102), phospholipids (DSPC), cholesterol (Chol), and dimyristic acryloyl-glycerol-PEG (DMG-PEG)—were prepared into stock solutions of 10 mg / ml. Solution A was prepared by mixing 110.4 μL of SM-102 stock solution, 24.6 μL of DSPC stock solution, 46.3 μL of cholesterol stock solution, and 11.7 μL of DMG-PEG stock solution with 7 μL of anhydrous ethanol. 100 μg of mRNA was mixed in 600 μL of citrate buffer (10 mM), and 200 μL of solution A was added while vortexing. The mixture was vortexed for another 20 seconds to obtain lipid nanoparticles.
[0041] The above preparation methods were used to prepare lipid nanoparticles loaded with GF mRNA, lipid nanoparticles loaded with GPC3-specific CAR mRNA, lipid nanoparticles loaded with MSLN-specific CAR mRNA, lipid nanoparticles loaded with anti-CD3 scFv mRNA, and lipid nanoparticles loaded with CD80 mRNA, respectively.
[0042] Example 1 1.1 The prepared lipid nanoparticles were co-incubated with BMDM for 24 hours (for those transfected with multiple mNRAs, the corresponding lipid nanoparticles were co-incubated with cells). Experimental results showed that GPC3-specific CAR (GPC3-CAR), MSLN-specific CAR (MSLN-CAR), anti-CD3 scFv (αCD3), and CD80 mRNA delivered via LNP were successfully expressed in C57BL / 6 mouse bone marrow-derived macrophages (BMDM). GPC3-CAR, MSLN-CAR, and αCD3 were expressed on the cell membrane, all being single-chain structures composed of heavy and light chains linked by a G4S linker. Therefore, GPC3-CAR, MSLN-CAR, and αCD3 could be detected by G4S flow cytometry. Flow cytometry results showed that after 24 hours of LNP addition, the expression of GPC3-CAR and αCD3 both reached over 70% (see appendix). Figure 2 In the A), MSLN-CAR expression can reach nearly 50% (see appendix). Figure 2 In B), compared with wild-type (WT) and GPC3-CAR-transferred BMDM, CD80 expression on the surface of BMDM co-transferred with αCD3 and CD80 (LNP αCD3-CD80) and co-transferred with GPC3-CAR, αCD3 and CD80 (LNP αCD3-CD80 GPC3-CAR) was significantly increased (see appendix). Figure 2 (C in the middle).
[0043] 1.2 The surface of BMDM expressing anti-CD3 scFv (αCD3) can directly bind to CD3+ T cells, indicating that the edited macrophages can act as connectors. After co-culturing C57BL / 6 mouse BMDM obtained above with CD3+ T cells derived from the spleen of C57BL / 6 mice sorted by magnetic beads for 12 hours, microscopic observation showed that the surface of BMDM expressing αCD3 could directly bind to several T cells, while the surface of BMDM not expressing αCD3 did not bind to T cells at all (see appendix). Figure 3 (AC in the image). Laser confocal microscopy also revealed T cells (CD3+) attached around BMDM (CD11b+) expressing αCD3. Figure 3 (D in the middle).
[0044] 1.3 After short-term (72h) and long-term (10d) co-culture of BMDM expressing different molecules with T cells, BMDM co-expressing αCD3 and CD80 showed better activation effects on T cells than BMDM expressing only αCD3, as evidenced by a significantly increased proportion of CD69+ T cells (see Appendix). Figure 4 (A and B in the text).
[0045] 1.4 T cells were pre-stained with CFSE, and then co-cultured with BMDM expressing different molecules for a short period (72 h). Flow cytometry analysis showed that BMDM co-expressing αCD3 and CD80 promoted T cell proliferation more effectively than BMDM expressing only αCD3 (see appendix). Figure 5 (A) After short-term co-culture of BMDM with T cells (72 h), T cells in the BMDM group, which co-expressed αCD3 and CD80, expressed more anti-apoptotic protein Bcl2 (see Appendix). Figure 5 The results suggest that T cells have a stronger anti-apoptotic ability after being stimulated by dual signals of αCD3 and CD80.
[0046] 1.5 After co-culturing T cells with BMDM expressing different molecules for 72 hours, the culture supernatant was collected, and the concentration of cytokines was detected by ELISA. The results showed that the level of IL2 secreted by T cells after αCD3+CD80 stimulation was significantly higher than that after αCD3 stimulation alone (see appendix). Figure 6 (B in the text). Additionally, αCD3+CD80 stimulation allows T cells to secrete more tumor-killing cytokines IFNr and granzyme B (see appendix). Figure 6 (A and C in the text).
[0047] 1.6 T cell activation requires a large amount of energy, and mitochondria provide ATP through oxidative phosphorylation (OXPHOS). After co-culturing T cells with BMDM co-expressing αCD3 and CD80 or BMDM expressing only αCD3 for 72 hours, the fluorescence intensity of Mitotracker Red CMXRos in T cells was detected by flow cytometry, representing the number of functionally active mitochondria. It was found that T cells co-cultured with BMDM co-expressing αCD3 and CD80 had more active mitochondrial function (see appendix). Figure 7 The result (A) indicates a higher level of T cell activation. Furthermore, after co-culturing T cells with BMDM cells co-expressing αCD3 and CD80 or BMDM cells expressing only αCD3 for 96 hours, Seahorse XF Pro analyzer results showed that, compared to T cells co-cultured with BMDM cells expressing only αCD3, T cells co-cultured with BMDM cells co-expressing αCD3 and CD80 had higher oxygen consumption rate (OCR), basal respiration, maximum respiratory capacity, and reserve respiratory capacity (see attached figure). Figure 7 The B and C values indicate an activated state characterized by high metabolism, high energy demand, and high metabolic flexibility.
[0048] 1.7 Using a lentiviral system, we overexpressed GPC3, a common target of human liver cancer, and MSLN, a common target of human ovarian cancer, on the surface of Hepa1-6 mouse hepatocellular carcinoma cells and ID8 mouse ovarian cancer cells, respectively. Flow cytometry analysis showed that the expression of both GPC3 and MSLN could reach over 98% (see Appendix). Figure 8 (A and B in the text).
[0049] 1.8 Six different combinations of mRNAs, including GFP, GPC3-CAR, αCD3, CD80, αCD3+CD80, and αCD3+CD80+GPC3-CAR, were delivered to BMDM via LNP. Twenty-four hours later, BMDM expressing different molecules was co-cultured with T cells and tumor cells at a BMDM:T:tumor cell ratio of 2:4:1. Tumor cells expressing two different antigens were used, including Hepa1-6 cells matched with CAR. GPC3+ and Hepa1-6 which are incompatible with CAR MSLN+ After 72 hours, the killing efficiency of different groups against tumor cells was detected by a luciferase assay. For Hepa1-6... GPC3+ Cells, the αCD3+CD80+GPC3-CAR group had the highest killing efficiency, and the αCD3+CD80 group had a significantly higher killing efficiency than the αCD3 group (see appendix). Figure 9 (A) in Hepa1-6. MSLN+ Cells still showed that the killing efficiency of the αCD3+CD80 group was significantly higher than that of the αCD3 group, and GPC3-CAR was ineffective against these cells (see appendix). Figure 9 (B in the middle).
[0050] 1.9 First, prepare Hepa1-6 GPC3+ Tumor cells were stained with Cell Tracker Green dye (0.5 μM) for 15 minutes. Then, BMDM was mixed with T cells and stained Hepa1-6 cells. GPC3+ Tumor cells were co-cultured in 24-well cell culture dishes at a BMDM:T:tumor cell ratio of 2:4:1, with cell crawling slides pre-laying the bottom of the dishes. Two hours later, LNPs delivering αCD3+CD80+GPC3-CAR were added to the co-culture system. After 24 hours, the culture medium was discarded, and the cells were washed three times with PBS, followed by fixation with 4% paraformaldehyde. Anti-CD3-FITC and anti-CD11b-PE-Cy7 antibodies were added at a 1:300 dilution and stained at room temperature for 30 minutes. After washing with PBS, Dapi staining was added for 5 minutes. The slides were then mounted and observed under a confocal microscope to examine the distribution and state of the cells. It was observed that T cells, BMDM, and tumor cells could form aggregates, and BMDM could engulf some tumor cells, such as… Figure 10As shown (cell aggregates in the co-culture system observed by confocal microscopy, where BMDM cells are labeled with CD11b antibody (green), T cells are labeled with CD3 antibody (red), and Hepa1-6 cells are labeled with Cell tracker). GPC3+ Tumor cells).
[0051] 1.10 Different mRNAs, including GFP, CD80, αCD3, and αCD3+CD80, were delivered to Hepa1-6-Luciferase-tdtomato tumor cells via LNP, with 1E5 tumor cells per well. Twelve hours later, 1E6 CD3+ T cells isolated from mouse spleens were added to each well. After 72 hours, the status of tumor cells in different groups was observed. It was found that tumor cells in both the αCD3 and αCD3+CD80 groups died, with significantly more severe cell death in the αCD3+CD80 group (see appendix). Figure 11 (A) The killing efficiency of tumor cells in different groups was detected by luciferase assay. Consistent with microscopic observation, both the αCD3 group and the αCD3+CD80 group showed killing effects, with the αCD3+CD80 group exhibiting significantly higher killing efficiency than the αCD3 group (see Appendix). Figure 11 (B in the middle).
[0052] 1.11 In mice Hepa1-6 GPC3+ In a Luciferase hepatocellular carcinoma model, liver tissue (including tumor tissue) was dissociated into a single-cell suspension 24 hours after tail vein injection of LNP αCD3-CD80-CAR mRNA (0.15 mg / kg) labeled with DID dye. Flow cytometry analysis was used to detect the distribution of LNP in different cell types. The results suggested that nearly one-third of CD45+ cells in the hepatocellular carcinoma tissue took up LNP (associated with tumor cells). Figure 12 (A in the text), and in CD45+ cells that have taken up LNP, the vast majority are myeloid cells such as macrophages, neutrophils, and monocytes (see appendix). Figure 12 (B) Similarly, in mouse ID8 MSLN+ In a Luciferase ovarian cancer model, LNP αCD3-CD80-CAR mRNA (0.15 mg / kg) labeled with DIO dye was injected intraperitoneally. Twenty-four hours later, peritoneal cells were retrieved and washed. It was observed that nearly two-thirds of the CD45+ cells in the peritoneal cavity had taken up LNP (with attached...). Figure 12 (C in the text), and in CD45+ cells that have taken up LNP, the vast majority are myeloid cells such as macrophages, neutrophils, and monocytes (see appendix). Figure 12 (D in the middle).
[0053] 1.12 Select several 6-8 week old female C57BL / 6 mice, and inject each mouse intraperitoneally with 5E7 doses of ID8. MSLN+ Ovarian cancer model was established using Luciferase-tdtomato cells. Six days later, tumor cell growth in mice was observed using bioimaging (BLI). Mice with successfully established models were randomly divided into three groups: GFP, αCD3, and αCD3-CD80-MSLN-CAR. Subsequently, treatment was administered via intraperitoneal injection of the corresponding LNP mRNA on days 1, 3, 5, and 7, with tumor growth monitored regularly via BLI. (See attached image) Figure 13 (A and B in the table). Statistical analysis of the results on days 3, 7, 14, and 21 of treatment showed that the αCD3 group had no significant therapeutic effect, while the αCD3-CD80-MSLN-CAR group showed significant therapeutic effect. Furthermore, on day 14 of treatment, several mice in the αCD3-CD80-MSLN-CAR group had tumor signal intensity reduced to 0, demonstrating significantly better efficacy than the αCD3 group (see attached table). Figure 13 (C) After imaging on day 21, mice were euthanized by cervical dislocation, and cells were extracted from the peritoneal cavity for T cell activation detection. Flow cytometry results showed that the activation rate of T cells in the αCD3-CD80-MSLN-CAR group was significantly higher than that in the αCD3 group (see attached image). Figure 13 (D in the middle).
[0054] 1.13 Select ID8 MSLN+ In the Luciferase-tdtomato ovarian cancer model, mice cured by αCD3-CD80-MSLN-CAR and age-matched healthy mice were each intraperitoneally injected with 2E6 ID8 molecules. MSLN+ - Luciferase-tdtomato cells were used to create an ovarian cancer model, and tumor growth was monitored regularly via BLI (see attached image). Figure 14 (A in the text). The results showed that at different detection time points, the tumor burden in the control group mice was significantly higher than that in the αCD3-CD80-MSLN-CAR cured group (see appendix). Figure 14 In the B and C groups (of the αCD3-CD80-MSLN-CAR group), mice in the D60 control group died first, and all died by D100, while 80% of the mice in the αCD3-CD80-MSLN-CAR cure group successfully resisted ovarian cancer implantation (see appendix). Figure 14 (D in the text). This indicates that αCD3-CD80-MSLN-CAR LNP can induce specific and durable immune memory, which is the ultimate goal pursued by immunotherapy.
[0055] 1.14 Select several 6-8 week old male C57BL / 6 mice, and inject each mouse intraperitoneally with 1E6 Hepa1-6. GPC3+- Luciferase cells were used to create an orthotopic liver cancer model in mice. Six days later, the growth of tumor cells in mice was observed using bioimaging (BLI). Mice with successfully induced models were randomly divided into GFP, αCD3, and CAR groups. αCD3 Three groups of CD80 were administered. Treatment then involved intravenous injection of the corresponding LNP mRNA on days 1, 3, 5, 7, 9, and 11, with tumor growth monitored regularly via BLI (see attached). Figure 15 A in the figure). Longitudinal BLI results show (attached) Figure 15 In mice in groups B), GFP, and αCD3, tumor burden increased rapidly after treatment began. From day 6, intraperitoneal bioluminescence signals significantly increased, and by day 9, most individuals showed diffuse high-intensity bioluminescence, indicating continued tumor progression. By day 12, a large number of mice in both groups died due to excessive tumor burden, and extensive tumor infiltration was observed in the surviving individuals. In contrast, CAR... αCD3 The CD80 group showed almost no significant enhancement of bioluminescent signal throughout the entire treatment observation period. Most mice maintained BLI intensity close to background levels from day 6 to day 26, suggesting that in situ tumor growth was significantly inhibited or even completely eliminated. Quantitative analysis of BLI at each time point further confirmed the above differences (see appendix). Figure 15 (C in the text). Survival analysis results were highly consistent with changes in tumor burden (see appendix). Figure 15 (D in the text). The GFP group mice had the shortest median survival time, with all individuals dying within approximately 30–40 days. The survival curves of the αCD3 group highly overlapped with those of the GFP group, and the difference between the two groups was not significant (ns), further demonstrating that αCD3 signaling alone does not improve prognosis. Conversely, CAR... αCD3 The CD80 group maintained a high survival rate at the observation cutoff point, and its survival curves showed a significant prolongation compared to the two control groups. Some individuals exhibited a trend toward long-term disease-free survival (see appendix). Figure 15 (D in the middle).
[0056] 1.15 In a liver cancer treatment model, mice in different groups were euthanized by cervical dislocation, and corresponding tumor tissues were extracted for multiplex immunofluorescence staining. The results showed that the composition of immune cell infiltration in the tumor tissues of each group differed significantly after LNP treatment. In the GFP control group and the αCD3 group, CD11b... + Myeloid cells (green) are sparsely distributed in the tumor stroma, CD8 + The overall level of T cell (purple) infiltration was low, with only a few scattered positive cells visible, suggesting that simple GFP or αCD3 expression did not effectively recruit cytotoxic T cells into the tumor site. In contrast, CAR... αCD3 A large number of CD8 groups were observed in tumor tissues containing CD80. + T cell aggregation was significantly higher than in the other two groups (see appendix). Figure 16 (AB in the image). Some myeloid cells and CD8 are visible. + T cells are spatially clustered in close proximity (see appendix) Figure 16 (C in the diagram is indicated by a dashed circle). In summary, this demonstrates that CAR expressed via in vivo LNP delivery... αCD3 CD80 can not only promote CD8 + Effector T cells efficiently infiltrate the tumor microenvironment and may also reshape the local myeloid-T cell immune ecology of the tumor, providing histological evidence for their significant anti-tumor effects.
[0057] 1.16 For the assessment of CAR αCD3 Long-term anti-tumor immune memory was observed in mice that achieved complete remission after CD80 mRNA LNP treatment. After a certain period of time following tumor clearance and complete remission, these mice (experimental group) and age-matched untreated mice (control group) were subcutaneously inoculated with homologous Hepa1-650%. GPC3+ -Luciferase tumor cells (1×10) 6 / each), and tumor volume was monitored regularly starting after vaccination (see attached). Figure 17 (A) The tumor volume change curve over time shows a significant difference in tumor growth kinetics between the experimental group and the control group (see Appendix). Figure 17 (B) In the control group mice, tumors showed continuous growth immediately after inoculation, with a significant increase in tumor volume from Day 7, and stable progression was observed from Day 18 to Day 27, suggesting that GPC3... + Hepa1 6. Cells lack effective innate immune control. Conversely, in the experimental group derived from CD3-CD80-MSLN-CAR-cured mice, almost no palpable or measurable subcutaneous tumor formation was observed throughout the follow-up period, and no delayed tumor recurrence was observed, indicating that an immune response to 50% homologous GPC3 had been established in vivo. + A highly protective immune state against tumors.
[0058] 1.17 Flow cytometry results showed that different mRNAs... Following LNP treatment, hepatocellular carcinoma tumors infiltrated CD8+. + Significant differences were observed in the activation levels of T cell effector functions. In the GFP control group, CD8... + IFN in T cells The proportion of γ-positive individuals was low; in the two groups expressing CAR or αCD3 alone, the IFN... γ + CD8 + The proportion of T cells was roughly the same as in the GFP group, with only a slight increase; the CD80 monotherapy group showed IFN. γ expression increased slightly further, but remained at a low level overall. Compared with the groups mentioned above, CAR... αCD3 CD80 combination group tumor tissue CD8 + T cell IFN γ expression was significantly enhanced, and quantitative analysis showed that IFN γ + Cells in CD8 + The proportion of T cells was significantly higher in the GFP, CAR, αCD3, and CD80 groups than in the GFP, CAR, αCD3, and CD80 groups, while there were no statistically significant differences among the four single-drug groups (see appendix). Figure 18 (A) The detection results of the degranulation activation marker CD107a were highly consistent with the above trend. GFP group CD8 + The proportion of CD107a positivity was lowest in T cells; CD107a was significantly reduced after treatment with CAR and αCD3 monotherapy. + CD8 + A slight increase in the proportion of T cells was observed; a further increase in CD80 was observed in the CD80 monotherapy group, suggesting that co-stimulatory signals have a certain promoting effect on cytotoxic potential. However, only in CAR... αCD3 In the CD80 combination set, CD107a + CD8 + The proportion of T cells increased significantly, and quantitative results showed that its level was significantly higher than that of all single-drug groups, while there were no significant differences among the GFP, CAR, αCD3, and CD80 groups (see appendix). Figure 18 (B) In summary, delivery of CAR, αCD3, or CD80 mRNA alone is insufficient to induce large-scale, fully functional cytotoxic CD8+ in the tumor local area. + T cells, and the combined delivery of CAR, αCD3, and CD80 via the same LNP platform in vivo, can synergistically and significantly enhance CD80. + IFN of T cells γ-ray production and degranulation capabilities significantly enhance tumor-invasive CD8+. + The cytotoxic effect of T cells provides an immunological basis for the superior antitumor activity exhibited by the combined formulation in vivo.
[0059] Flow cytometry analysis (1.18) showed that treatment with different mRNA LNPs resulted in differential changes in local T cell memory differentiation, the proportion of immunosuppressive cells, and the composition of myeloid / innate immune cells in liver cancer tumors (see appendix). Figure 19 AC in the context of memory T cells (see appendix). Figure 19 A), GFP control group tumor infiltration CD8 + T and CD4 + CD44highCD62L in T cells + The proportion of memory-like cells was consistently low; after delivery of CAR or αCD3 alone, the proportion of these memory phenotypes increased slightly compared to the GFP group, but the differences were not statistically significant (ns), and the CD80 monotherapy group also showed only a mild upward trend. In contrast, CAR... αCD3 CD80 Combination Set includes CD44^highCD62L + CD8 + T cell frequency increased significantly, approximately 1.5–2 times that of GFP and each single-drug group, with highly statistically significant differences; CD4 + The proportion of memory-like subsets in T cells was also significantly increased. These results suggest that only under conditions of simultaneous CAR targeting, αCD3 redirection, and CD80 co-stimulation can a tumor-specific population of T cells with memory / long-term response potential be effectively enriched. Regarding immunosuppression and effector function (see appendix) Figure 19 B), GFP control group CD4 + Foxp3 in T cells + The proportion of regulatory T cells (Tregs) was relatively high; CAR or αCD3 monotherapy did not significantly reduce Treg frequency (ns), and CD80 monotherapy also showed only a slight decrease. However, in the CAR group... αCD3 In the CD80 group, Foxp3 + CD4 + The proportion of T cells decreased significantly, showing significant or highly significant differences compared to the GFP group and the CAR and αCD3 monotherapy groups, suggesting that combination therapy can effectively alleviate Treg-mediated local immunosuppression. Correspondingly, CD8... + perforin in T cells + The proportion of cells in CAR αCD3 The CD80 group showed significantly higher levels than the GFP control and most single-drug groups, while there were no significant differences among the GFP, CAR, and αCD3 groups, indicating that combination therapy not only reduces inhibitory CD40 but also...+ T cells, accompanied by cytotoxic CD8 + Enhanced T-cell killing effect. Further analysis of tumor-associated myeloid and innate immune cells (see appendix). Figure 19 Figure C) shows that the geometric mean fluorescence intensity (MFI) of CD206 in the tumor tissue of the GFP group was higher, suggesting a larger proportion of M2 tumor-associated macrophages (TAMs). In the CAR, αCD3, and CD80 single-drug groups, the expression levels of CD206 were similar to those in the GFP group, with no significant decrease observed. However, in the CAR group… αCD3 In the CD80 group, CD206 MFI was significantly reduced, suggesting immunosuppressive M2. TAM was effectively weakened. Neutrophils (CD11b) + Ly6G + Regarding GFP, the proportion of the control group was relatively high, and single-drug treatment did not significantly change its infiltration level; CAR αCD3 The proportion of neutrophils was significantly lower in the CD80 group, indicating that combination therapy helps reduce pro-tumor neutrophils associated with tumor progression. In contrast, the proportion of CD3 neutrophils was significantly lower in all groups. - NK1.1 + The proportion of natural killer (NK) cells did not differ significantly, suggesting that NK cells were not the primary effector population affected at this model and at the detection time point. In summary, these results indicate that delivery of CAR, αCD3, or CD80 mRNA alone has limited effect on the overall remodeling of the tumor microenvironment, while CAR... αCD3 The combined delivery of CD80 and the other two significantly amplified tumor-invasive memory-like CD4. + / CD8 + The T cell population enhanced the cytotoxic T cell effect while also effectively inhibiting Treg and M2 cells. Immunosuppressive / tumor-promoting components such as macrophages and neutrophils promote the transformation of the tumor microenvironment towards a direction conducive to anti-tumor immune responses from multiple levels.
[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A lipid nanoparticle, characterized in that, The lipid nanoparticles encapsulate the mRNA of the chimeric antigen receptor targeting tumor cells, CD80 mRNA, and the mRNA of the anti-CD3 single-chain antibody.
2. The lipid nanoparticles according to claim 1, characterized in that, The tumors include liver cancer and ovarian cancer.
3. The lipid nanoparticles according to claim 2, characterized in that, The amino acid sequence of the mRNA-encoded protein of the chimeric antigen receptor targeting liver cancer cells is shown in SEQ ID NO.
1.
4. The lipid nanoparticles according to claim 2, characterized in that, The amino acid sequence of the mRNA-encoded protein targeting the chimeric antigen receptor for ovarian cancer cells is shown in SEQ ID NO.
2.
5. The lipid nanoparticles according to claim 1, characterized in that, The amino acid sequence of the protein encoded by the CD80 mRNA is shown in SEQ ID NO.
3.
6. The lipid nanoparticles according to claim 1, characterized in that, The amino acid sequence of the mRNA-encoded protein of the anti-CD3 single-chain antibody is shown in SEQ ID NO.
4.
7. The lipid nanoparticles according to claim 1, characterized in that, The lipid nanoparticles include ionizable lipids, phospholipids, cholesterol, and dimyristic-rac-glycerol-PEG.
8. The lipid nanoparticles according to claim 7, characterized in that, The molar ratio of the ionizable lipids, phospholipids, cholesterol, and dimyristic-rac-glycerol-PEG is 50:10:38.5:1.
5.
9. The use of the lipid nanoparticles according to any one of claims 1-8 in the preparation of products for treating tumors.
10. An engineered macrophage with connector function, characterized in that, The engineered macrophages are macrophages expressing the chimeric antigen receptor, CD80, and anti-CD3 single-chain antibody targeting tumor cells as described in claim 1.
